Nanoparticle Tracking Analysis – A Novel Technique for Exosomes Research
Conference Recording Sep 30, 2013
About the Speaker
Dr Thomas Benen’s background is in molecular biology, with expertise in the optical analysis of cells and virus-like particles. He was trained in genetics and bioinformatics, and holds an MSc from the University of Regensburg and a PhD from the University of Hamburg. Thomas was funded by the Bill and Melinda Gates foundation to develop a novel molecular display technique on the basis of lentiviral particles for the affinity maturation of viral antigens. This method is now being used in the development of HIV vaccine prototypes. In parallel, he gathered experience in project management for several years at the start-up incubator BioPark Regensburg GmbH, where he initiated marketing campaigns and supported interdisciplinary projects with Capgemini Consulting. The incubator was able to triple the number of tenants, floor space and network partners during this time. He joined Nanosight in 2012 and is responsible for sales and scientific support in Northern Germany.
The technique of Nanoparticle Tracking Analysis from NanoSight Ltd is a recently developed method which is being rapidly adopted for the analysis and counting of exosomes and microvesicles. Based on a unique microscopical laser illumination configuration, this technique allows biological nanoparticles in a sample to be simultaneously but individually visualised, sized (through video analysis of their Brownian motion) and counted in real time and in complex backgrounds. Furthermore, it is capable of detecting and analysing fluorescently labelled exosomes and microvesicles allowing for phenotyping of subpopulations of such structures in clinical samples. The technique will be described and selected examples will be shown from the 250+ papers describing the use of NTA in the routine analysis of biological samples of clinical significance in a wide range of applications concentrating on the use of exosomes and microvesicles in diagnosis and therapeutics.